Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

It is beyond the scope of this paper to cover every type of disability. Thus, this review will focus on categories of disability that are both common in reproductive-aged women and that pose ...